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A B S T R A C T
Acetylsalicylic acid is used as a non-steroidal anti-inflammatory drugs (NSAID) and antiplatelet agents by in-
hibiting cyclooxygenases. However, therapy using acetylsalicylic acid could induce gastric bleeding and cause
other gastrointestinal toxicity. The aim of this study was to demonstrate the synthesis of a new compound
bearing salicylic acid residue namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid, to analyze its potential as a
ligand for human cyclooxygenase-2 (COX-2) receptor, to evaluate its toxicity level and its effectiveness for
analgesic and antiplatelet agent compared with acetylsalicylic acid.
Synthesis of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid was conducted by microwave irradiation. The
purity of this compound was evaluated with TLC, IR, NMR, and EDS spectroscopy. The chemical characterization
and docking studies against human COX-2 (PDB:5F1A) was performed in-silico. The acute oral toxicity assay was
performed under OECD guidelines. The analgesic activity study was performed by plantar and writhing test on
animal model. For anti-platelet activity study, we performed tail-bleeding assay and flow cytometry based
platelet aggregation assay. We could successfully synthesize a pure white crystalline 2-((3-(chloromethyl)ben-
zoyl)oxy)benzoic acid. In-Silico G-Score result of those compounds gives us preliminary hint of the potential
affinity of this compound as a ligand for COX-2 receptor (PDB: 5F1A). Acute toxicity and microscopic gastro-
intestinal assessments indicated non-observable harmful toxicity parameters. The plantar response time of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid treated groups showed a significant increment (P < 0.01), and the
nociceptive response in writhing test demonstrated a significant dose-dependent decrement. This indicated that
its analgesic activity was better than acetylsalicylic acid. The platelet aggregation of 2-((3-(chloromethyl)ben-
zoyl)oxy)benzoic acid was lower than its controls, indicating an aggregation inhibition pattern. The animals
treated with 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid gave a longer bleeding time. Overall, this study
demonstrated a successful synthesis of pure 2-((3-(chloromethyl)benzoyl)oxy) benzoic acid. We postulated that
this compound was better than acetylsalicylic acid, exhibiting excellent analgesic and antiplatelet activity with
no toxicity impact.
1. Introduction
Over decades, a compound bearing salicylic acid residue namely
acetylsalicylic acid is used as a non-steroidal anti-inflammatory drugs
(NSAID) and antiplatelet agent due to its unique capability in inhibiting
cyclooxygenases (COX). Recent studies showed that acetylsalicylic acid
treatment can improve bone regeneration, particularly in inflammatory
conditions [1]. One symptomatic character of inflammation such as
pain could be reduced by the analgesic action of acetylsalicylic acid [2].
Despite its cardioprotective effects and ability to inhibit inflamma-
tion, many studies have reported the dose-dependent harmful impact of
acetylsalicylic acid on the gastrointestinal tract, ranging from mild
upper gastrointestinal problem to severe peptic ulcer disease [3]. To
maintain the benefit of acetylsalicylic acid and minimize its harmful
effects,
the present work reported the synthesis of a new compound bearing
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salicylic acid residue, so-called 2-((3-(chloromethyl)benzoyl)oxy)ben-
zoic acid, followed by the evaluation of its purity, analgesic and anti-
platelet aggregation activities. The discovery of 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid was based on preliminary in-silico drug
modification study design. The structure of salicylic acid was modified,
particularly the benzoyl-group attacking the phenolic OH-group within
salicylic acid. The structure modification (supplemental Fig. 1) was
conducted in 3 different zones with 4 different substituent (Cl, CH3,
CH2Cl, and H). The choice of substituent was based on its positive li-
pophilic (π) constants grades, which could increase the ability of the
new compounds to enter the cell membranes. During the modification
experiments, 64 new compounds were generated. In-Silico studies of
those compounds give preliminary hint of the potential activity of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid as a ligand for COX-2 receptor
protein (PDB: 5F1A) in homeostasis such as inhibiting the platelet ag-
gregation.
Platelet is the most essential blood cells responsible for homeostasis.
The treatment of 150 μmol/kg BW acetylsalicylic acid could prevent the
platelet aggregation in-vitro, inhibit blood coagulation, and prevent
thrombus formation inside the blood capillary. Thus it is very suitable
for the treatment of patients with cardiovascular disease and stroke [4].
Platelet function studies can be performed indirectly by bleeding time
assay and directly by platelet aggregation assay. Recently, a novel flow
cytometry-based platelet aggregation assay was developed to allow the
detection of platelet aggregates with small blood volumes and low
platelet numbers, enabling the assessment of its direct function in
human and animal models [5]. This technique employs whole blood or
plasma contains labeled platelets with different fluorochromes. After
mixing and upon appropriate stimulation, in-vitro aggregation pattern
can be interpreted from the formation of double-colored aggregate.
2. Materials and methods
2.1. General Procedure for the Synthesis of 2-((3-(chloromethyl)benzoyl)
oxy)benzoic acid
An amount of 0.25 g salicylic acid (1.8 mmol) was mixed in a con-
secutive manner with 1ml of 3-chloromethylbenzoylchloride
(7.2 mmol), 0.14ml of pyridine, 1.1 ml of acetone, and then was
homogenized in an erlenmeyer tube. The reaction was generated by
5min exposure of microwave irradiation with a Millstone Organic
Synthesis Unit (MicroSYNTH) with a touch control terminal followed
by further preparation [14]. The reaction mixture was placed in the
microwave oven (600W) for 1min. Then, the mixture was removed
from the microwave oven, stirred, and again placed in the microwave
(600W) for 1min. After this period, microwave irradiation was con-
tinued and the reaction mixture was monitored every 1min using thin-
layer chromatography (TLC) with a stationary phase of silica gel F254
and a mobile phase of hexane–ethanol (1:2, v/v). The ferric chloride
(FeCl3) test was also used to identify the presence of salicylic acid in the
reaction mixture every minute. The initial mixture formed slurry, and
after microwave irradiation it became a homogeneous solution. The
presence of the product was demonstrated by the formation of solid.
The reaction condition has been optimized, by controlling the reaction
time and the yield of the product.
2.2. Characterization of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
Melting points were determined using a Melting Point
Electrothermal Apparatus (Büchi B540, Sigma Aldrich, Switzerland)
and were uncorrected. The elemental analysis (C, O, Cl) was performed
using The Element Energy Dispersive Spectroscopy (EDS) EDAX-
APOLLO-X (Ametex, Berwyn, PA, USA). IR spectra were recorded from
4000 to 400 cm−1 with a Perkin Elmer System 60825 (Devon, UK). The
spectra of 1H and 13CNMR were recorded on a Jeol JNM–ECS 400
spectrometer (Jeol Ltd., Akishima, Japan), operated at room
temperature (400 and 100MHz for 1H and 13C spectroscopy respec-
tively). Chemical shift (δ) is expressed in part per million.
2.3. In-silico analysis of physicochemical activities of 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid
The physicochemical properties of 2-((3-(chloromethyl)benzoyl)
oxy)benzoic acid compared to acetylsalicylic acid were analyzed by
ChemDraw Ultra 8.0 and Chem3D Ultra 8.0 (Perkin Elmer, Waltham,
USA) and MarvinSketch 15.2.16 (ChemAxon Ltd, Budapest, Hungary).
The docking of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
(compared to acetylsalicylic acid) on the COX-2 receptor protein (PDB:
5F1A) was performed using Glide (Grid-Based Ligand Docking with
Energetic) 4.0, Extra Precision (Glide 4.0 XP) docking (Schrödinger
software, New York, USA). Ligand was minimized using OPLS-AA force
field, meanwhile the cyclooxygenase protein was prepared by protein
preparation wizard (Molecular Mechanics), provided with Glide. The
system was minimized with Root Mean Square Deviation (RMSD)
0.30 Å.
2.4. Animal model
For pharmacological and physiological experiments, 6 to 8 week old
mice weighing 20 g and Wistar rats weighing 200 g aged 6–8 weeks old
were obtained from Pusvetma (Surabaya, Indonesia). Animals were
housed in a temperature-controlled (20–24 °C) room, relative humidity
65%, with a 12-h light/dark cycle and allowed to consume food and
water ad libitum. This study was approved by The University of Gadjah
Mada Committee on the Use and Care of Animals. On the day of the
experiment, a certain number of animal was divided into several ap-
propriate groups and treated as described in each section below.
2.5. Acute oral toxicity test
An acute oral toxicity study was performed according to the
Organization for Economic Cooperation and Development (OECD)
Guidelines 423 (2001) with a slight modification in the number of ex-
perimental mice. Thirty animals were divided into three groups. Before
the administration of compounds, mice were fasted for 2 h. In the
treatment group, mice were treated with 2000mg/kg bw of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid suspended in 1ml of 3% PGA
orally. The other 2 control groups were as follows: (1) mice were
treated with 2000mg/kg bw of acetylsalicylic acid suspended in 1ml of
3% PGA as positive control group, and (2) mice were administered with
1ml of 3% PGA suspension as negative control group. Following
treatment, animals were continuously observed throughout the first
30min and periodically observed during the early 24 h with particular
attention during the first 4 h. Afterwards, the gross behavioral changes
(loss of appetite, hair erection, lacrimation, tremors, convulsions, sali-
vation, diarrhea, mortality, and other signs of toxicity manifestation) of
animals were observed daily for 14 days [6].
2.6. Gastric toxicity and histopathological analysis
Thirty male and female rats were divided into three groups equally
and treated with the compounds as described above orally, with a single
dose of 50mg/kg BW of each compound. The dosage used was based on
comparable dosage of 50mg/kg rat body weight to ˜500mg/70 kg
human body weight. After continuous treatment for seven days, the
animals were anaesthetized with 0.1 ml of ketamine 100mg/kg bw
intraperitoneally for abdominal dissection. To obtain paraffin em-
bedded whole gastric tissue, the fresh tissue was sunk directly into 0.5%
formalin for 10min. After fixation with paraffin block, microdissection
with 6 μm thickness and several dehydration steps, the probes were
colored with routine Hematoxylin-Eosin technique. The gastric toxicity
indices were measured through light-microscopical observation of
Caroline, et al. Prostaglandins and Other Lipid Mediators 145 (2019) 106364
2
gastric mucosal layer disruption followed by visual scoring according to
Zhang et al. [7].
2.7. Analgesic activity using plantar test and writhing test
The analgesic activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid was evaluated by using two methods, namely plantar test and
acetic acid-induced writhing test [8]. In plantar test, cutaneous hy-
peralgesia to thermal stimulation in unrestrained rats was measured
and especially used to evaluate the central action of the 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid. Animals were divided into three
experimental groups. Before treatment, rats were fasted for 2 h. In the
first group, six male rats were treated orally with vehicle namely 3%
Pulvis Gummi Arabicum (PGA) as negative control. In the second and
third groups, animals were divided into five sub-groups received acet-
ylsalicylic acid or 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid. Each
sub-group consisting of six animals were treated orally with 5 different
doses (12.5; 25; 50; 100; and 200mg/kg body weight) to generate ED50
value. The dosage range was based on comparable dosage of 50mg/kg
rat body weight to ˜500mg/70 kg human body weight with additional
two stepwise half-value dosage ranges (lower and higher dosage).
Thirty minutes after drug administration, rats were transferred to
Plantar Aesthesiometer serial 7370 (Ugo Basile, Camerio, Italy), and
adapted into the equipment for 10min. After the heat induction of
55–56 °C, the animal response was observed and documented every
10min for 1 h.
The analgesic activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid was evaluated in male mice with writhing test, as described by
Turner [9] and Faujdar et al. [8] to evaluate the peripheral action of 2-
((3-(chloromethyl)benzoyl)oxy)benzoic acid in mice. The mice were
divided into three experimental groups. Before treatment, mice were
fasted for 2 h. In the first group, six male mice were treated with vehicle
(3% PGA) intraperitoneally as negative control. In the second and third
groups, animals were divided into five sub-groups receiving acet-
ylsalicylic acid or 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid. Each
sub-group consisting of six animals were treated with 5 different doses
(12.5; 25; 50; 100; and 200mg/kg bw). Thirty minutes after drug ad-
ministration, 0.1ml of 0.6% acetic acid was injected for the induction
of writhings. The writhing effect was stimulated by stretching of at least
one hind limb. The animal response was observed for 10min, and the
reduction in the number of writhings in each group was recorded and
compared.
2.8. Animal treatment for bleeding time and flow cytometry assay
Sixty male mice were divided into 3 groups. Before the adminis-
tration of compounds, mice were fasted for 2 h. Each group was then
divided into 2 sub-groups in an equal number, used for bleeding time
test and flow cytometry assay. In the first group, mice were treated
orally with 0.58mmol/kg bw of acetylsalicylic acid suspended in 1ml
of 3%PGA as positive control. In another groups, mice were treated
with equimolar 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid sus-
pended in 1ml of 3% PGA or 1ml of vehicle (3% PGA only). The ex-
periments commenced 30min after drug administration.
2.9. Bleeding time assay
To assess the blood anticoagulation effect of each compound in vivo,
mice were anesthetized intraperitoneally using 0.1 ml of ketamine
100mg/kg bw, and positioned horizontally on a platform allowing the
tail to drop about 2 cm from the top of the platform. The experimental
procedure in detail was performed as described with minor modifica-
tions. To evaluate bleeding from the incision, Whatman filter paper
(Whatman International Ltd, Maidstone, UK) was applied to the edge of
the forming clot every 30 s. The blood was allowed to fall separately
from the cut during the 30-second interval. Data were expressed as
mean bleeding time (min) of each group after incision.
2.10. Preparation of mouse platelet-rich plasma (PRP) for flow cytometry
assay
After bleeding time assay, whole blood was collected by cardiac
puncture and collected in heparinized mouse blood collection tubes.
The whole blood was diluted with 2 fold volume of HEPES medium.
Diluted blood was centrifuged for 15min at 50 g, and the collected
platelet-rich plasma (PRP) was diluted further in HEPES medium to a
final concentration of 50×106 plt/ml. Mouse PRP was incubated at
room temperature with 1:100 dilutions of fluorochrome-labeled platelet
markers of CD31-APC and CD31-PECy7 monoclonal antibodies (Abcam,
Cambridge, UK) for 15min. After incubation, samples were centrifuged
for 5min at 2250 g and re-suspended in HEPES medium supplemented
to a concentration of 50× 106 plt/ml.
2.11. Aggregation assay and flow cytometric analysis
For specific platelet aggregation function test, the two populations
of labeled-washed mouse platelets were mixed in 1:1 ratio and then pre-
incubated for 15min at 37 °C while shaking (600 rpm). Pre-incubated
platelets were activated using 10mg/ml of type-I collagen (Sigma-
Aldrich, St.Louis, MO, USA) at 37 °C while shaking at 1000 rpm. Fixed
samples were measured and analyzed by BD FACS Calibur flow cyto-
metry (BD Biosciences, San Jose, CA, USA), equipped with FlowJo
version 9.2 software (Tree Star, inc., Ashland, OR, USA). For analysis, a
quadrant was set in the dot plot of respective channels on non-stimu-
lated platelets. The appearance of double-colored events in the upper
right quadrant (Q2) was quantified as total aggregation events and
calculated as described.
2.12. Statistics
Statistical analysis was performed with ANOVA. The data subsets
were graphically presented with GraphPad Prism Software v.7 (La
Jolla, CA, USA).
3. Results
3.1. Characterization of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
The synthesis yielded white crystalline solid 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid with melting point of 129 -1310C. The ab-
solute yield obtained from the above reaction was 73.27 ± 4.66%,
Analytical calculation for 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid (C15H11ClO4): C, 61.98; O, 22.02, Cl, 12.20%. Found: C, 62.10; O,
22.16, Cl, 12.87%
IR (KBr pellet, cm−1) data: 1732 (C=O ester), 1298, 1279, 1262
(C–O ester), 1694 (C=O carboxylic), 1262 (C–O carboxylic), 704 (C-
Cl), 1606 (C=C aromatic).
1H NMR (Acetone-d6, J, δ): 8.22 (t,1,9 Hz,1 H), 8.16 – 8.03(m, 2 H),
7.78 (d,7,8 Hz, 1 H), 7.70 (td, 7.8, 2.0 Hz, 1 H), 7.51 (dt, 61.7, 7.6 Hz,
3 H), 7.35 (d, 8.3 Hz, 1 H), 4.83 (s, 1 H).
13C NMR (Acetone-d6, δ, ppm): 20,553 (s, C=O), 164.98 (s,
-C=O), 151.11(s, -C-O), 138.87(s,-C−CH2), 134.00 (s,-C=C-),
133.87 (s,-C=C-), 131.90 (s,-C=C-), 130.53(s,-C=C-), 130.26 (s,-
C=C-), 129.98 (s,-C=C-), 129.23(s,-C=C-), 126.26 (s,-C=C-),
124.13(s,-C=C-), 124.10 (s,-C=C-), 45.29 (s,-C-Cl)
3.2. Physicochemical Properties and in-Silico Analysis of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid
The physicochemical properties of 2-((3-(chloromethyl)benzoyl)
oxy)benzoic acid were compared to acetylsalicylic acid by using
Chemdraw Ultra 8.0, Chem3D Ultra 8.0 (Perkin Elmer, Waltham, USA)
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and MarvinSketch 15.2.16 (ChemAxon Ltd, Budapest, Hungary). The
general parameters of physicochemical properties, such as lipophilic
parameter (CLogP), electronic parameter (polarization), and steric
parameter (CMR), were based on previously reported symbols [10]. It
was reported that 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid has
CLogP value= 3.495; polarizability= 28.42; and CMR=7.4602.
Those values were better than acetylsalicylic acid values (CLogP
value=0.804; polarizability= 17.06; and CMR=4.4576).
The docking of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid on
the COX-2 receptor protein (PDB: 5F1A; Fig. 1) showed that 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid (G Score – 9.48 kcal/mole)
had better affinity than acetylsalicylic acid (GScore - 5.88 kcal/mole).
3.3. Acute oral toxicity and histopathological analysis
The acute toxicity test revealed that oral administration of a single
dose (2000mg/kg bw) of 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid in mice did not show any signs of toxicity or mortality in treated
animals during 14 day observation period (data was not shown). In the
histopathological investigation of Wistar rats (Fig. 2), the micro-
anatomy of gastric tissue did not demonstrate any significant treatment-
related adverse effect in the animals receiving 50mg/kg bw of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid (Fig. 2C), comparison to ve-
hicle control (Fig. 2A). As expected, the assessment result of animals
receiving 50mg/kg bw dose of acetylsalicylic acid showed significant
disruption of mucosal epithelial layer, indicating the formation of
gastric ulcer (Fig. 2B).
3.4. Analgesic activity
Oral administration of 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid on heat induced rats in Plantar Anasthesiometer showed the dose-
dependent increase of nociceptive response time (Fig. 3). The response
time of each 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid groups in
various dosages showed a significant (P < 0.01) increase compared
with acetylsalicylic acid group. Following the induction of 0.6% acetic
acid in writhing test (Fig. 4), 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid group showed a significant dose-dependent decrease of nociceptive
response count compared with acetylsalicylic acid treated group
(P < 0.01).
3.5. Flow cytometry based platelet aggregation assay
Fig. 5a shows representative dot-plot data of murine platelet ag-
gregation pattern after in-vitro incubation of platelet with various
compounds using CD31-APC and CD31-PECy7 as antibodies. Upon
stimulation with collagen, the visual appearance of double-colored
events (upper right box) in 2-((3-(chloromethyl)benzoyl)oxy)benzoic
Fig. 1. In-silico docking of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid into
cyclooxygenase-2 (COX-2) protein receptors (PDB: 5F1A). The green pattern
represents one 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid. Grey pattern
represents the cyclooxygenase-2 protein. The ride lines represent oxygen. (For
interpretation of the references to color in this figure legend, the reader is re-
ferred to the web version of this article).
Fig. 2. Acute oral toxicity evaluation of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid in rat gastric mucosal layer. The 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid did not disrupt rat gastric mucosal layer. Representative histochemical staining of rat gastric mucosal layer with H&E. Rats were treated continuously for 7 days
with (A) Suspending agent of 3% PGA as vehicle, (B) 50mg/kg bw of acetylsalicylic acid (ASA) and (C) 50mg/kg bw of 2-((3-(chloromethyl)benzoyl)oxy)benzoic
acid (3 −CH2Cl). Black arrow: mucosal layer with major disruption, as indicated in ASA treated rat. Scale bar =1mm.
Fig. 3. Analgesic effects of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid and
acetylsalicylic acid in rats with Plantar Anesthesiometer (Ugo Basile, Comerio,
Italy). The line graphs show rat response time 30min after oral administration
of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3 −CH2Cl, white circle) and
acetylsalicylic acid (ASA, black circle) in different dosages (12.5, 25, 50, 100, or
200mg/kg bw). Data are presented as mean ± SEM (n=6).
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acid (3 CH2Cl) and acetylsalicylic acid (ASA) treated platelets was de-
creased compared with vehicle. The percentage of double-colored
events from 30 mice (10 mice per group) were analyzed as shown in
Fig. 5b. In accordance with its representative data, the total percentage
of platelet aggregation events of acetylsalicylic acid (ASA
0.92 ± 0.03%) and 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3
CH2Cl 0.87 ± 0.03%) was significantly lower than its negative control
(vehicle; 2.7 ± 0.06%), indicating a significant aggregation inhibition
pattern on those two compounds (P < 0.05).
3.6. Tail bleeding time assay
Representative tail bleeding time analysis of 30 mice (10 mice per
group) as shown in Fig. 6a showed a longer bleeding time pattern in
mice after the oral administration of acetylsalicylic acid (t= 840 s) and
2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3 CH2Cl; t= 870 s),
compared with its negative control (vehicle; t= 870 s). The statistical
analysis of multiple data as illustrated in Fig. 6b showed the same re-
sults. Acetylsalicylic acid (ASA; t= 750 ± 130.8 s) and 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid (3 CH2Cl; t= 860 ± 45.8 s) treated
animals demonstrated significantly longer bleeding time than its ne-
gative control (vehicle; 480 ± 103.9 s). The bleeding pattern of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid in the treated animals seemed
to be more in amount compared with acetylsalicylic acid treated group.
4. Discussion
4.1. Characterization of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
We have successfully synthesized a pure salicylic acid derivate
compound namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid. The
synthesis of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid was carried
out based on modified Schotten-Baumann acylation reaction [11,12],
with the use of biphasic aqueous basic conditions
2-((3-(chloromethyl)benzoyl)oxy)benzoic acid was formed sponta-
neously when 3-chloromethylbenzoylchloride reacted with salicylic
acid. However the esters were sensitive to acid and diminished the yield
of reaction. A tertiary amine like pyridine was added to the reaction
mixture as a solvent to neutralize the acid (Scheme 1). As a catalyst for
the reaction, we used pyridine directly to salicylic acid. Pyridine could
form a stable pyridinium chloride ion by binding to free hydrogen ion
from salicylic acid and free chloride ion from 3-chloromethylbenzoyl
chloride to prevent the spontaneous hydrolysis of 2-(3-(chloromethyl)
benzoyloxy)benzoic acid (supplemental Fig. 2). Pyridine could convert
benzoylchloride moieties into a good leaving group [11,12].
In this paper, we have modified our previously reported reflux
method [13] with microwave irradiation method that has been de-
scribed previously with acetylsalicylic acid and many other compounds
([14] [15];). The use of acetone as a solvent of the reaction and the
resulting residue was significantly reduced, and therefore resulting in a
better environmental impact.
The product yield of this method (73.27 ± 4.66%) was higher than
the reflux method (67.75 ± 1.77%). The time required to accomplish a
complete reaction was very rapid and significantly reduced in com-
parison to the previous method. Meanwhile the reflux-irradiation took
up to 6 h reaction time, whereas microwave irradiation took only 5min
reaction time.
4.2. Physicochemical Properties and in-Silico Analysis of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid
Based on the theoretical lipophilic parameter results, our newly
synthesized compound 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
(CLogP= 3.495) showed a greater value, indicating a more non-polar
properties than acetylsalicylic acid (CLogP=0.804). The higher lipo-
philic parameter of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
could increase its capability to enter the cytoplasm through the cell
membranes [16].
Furthermore, the electronic and steric parameters of 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid (polarizability= 28.42;
CMR=7.4602) also demonstrated a higher value than acetylsalicylic
acid (polarizability= 28.42; CMR=7.4602). These results open a new
hypothesis that our newly synthesized compound 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid could interact better with its cellular receptor
with higher affinity and activity [10].
The in-silico docking experiment of 2-((3-(chloromethyl)benzoyl)
oxy)benzoic acid to its hypothetical receptor cyclooxygenase-2 (COX-2)
was conducted using Glide 4.0 XP licensed by Schrödinger (New York,
USA). Glide has numerous advantage compared with numerous com-
mercial software. This program has been designed to perform as close to
an exhaustive search of the conformational, orientational and positional
space of the docked ligand and was found to be more accurate than the
GOLD, FlexX and DOCK [17]. To generate preliminary data regarding
the interaction of our compound with COX-2, we considered GlideScore
(GScore) as the scoring parameter to predict its affinity. GlideScore
measures the approximate ligand binding free energy, including its
electrostatic and van der Waals force fields [18]. Therefore a smaller
GScore value shows better affinity between ligand and its receptor.
Theoretically, our results predicted that 2-((3-(chloromethyl)benzoyl)
oxy)benzoic acid (G Score – 9.48 kcal/mole) has better affinity to its
target receptor COX-2 than acetylsalicylic acid (GScore - 5.88 kcal/
mole).
4.3. Acute oral toxicity and histopathological analysis
In this study, acute oral toxicity test indicated no harmful toxicity
parameters following the administration of 2-((3-(chloromethyl)ben-
zoyl)oxy)benzoic acid. Furthermore, the lethal dose (LD50) of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid ranged below 2000mg/kg
bw, which is identical to acetylsalicylic acid.
Numerous NSAIDs targeted on cyclooxygenases inhibition to gen-
erate analgesic effect and alleviate the symptoms of inflammation. It is
well known that the therapeutic administration of non-selective COX
inhibitor such as acetylsalicylic acid could induce gastric ulcer. Our
histopathological results as shown in Fig. 2 particularly on 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid treatment suggested that we
could exclude the harmful effect of acetylsalicylic acid by adding a new
substitute 3-chloromethylbenzoyl, to its main component of salicylate.
Fig. 4. Analgesic effects of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3
−CH2Cl) and acetylsalicylic acid (ASA) in mice with writhing test. Before ex-
perimental set-up, mice were administered orally with 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid (3 −CH2Cl ; white circle) or acetylsalicylic acid
(ASA, black circle) for 30min in different dosages (12.5, 25, 50, 100, or
200mg/kg bw).The line graphs show mice nociceptive response count after
stretching of at least one hind limb to stimulate the writhing. Data are presented
as mean ± SEM (n=6).
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On the account of the fact that the inhibition of COX-2 could success-
fully exhibit analgesic and antiinflammatory effect, the inhibition of
COX-1 by acetylsalicylic acid leads to disruption of the integrity of
healthy gastric mucosal layer [19]. Our results showed a trend that the
action of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid had a lower
interaction with gastric COX-1, presumably resulted in the partial in-
hibition of its function and therefore it could maintain the integrity of
gastric mucosal membrane (supplemental Fig. 3).
4.4. Analgesic activity
The dose-dependent increase of 2-((3-(chloromethyl)benzoyl)oxy)
benzoic acid nociceptive response on heat induced rats in Plantar
Anesthesiometer gave us a primary evidence of the analgesic effect of
our newly synthesized drug to the pheriperal nervous system response.
Under peripheral analgesic effect, the animal models were significantly
more resistant to peripheral heat sensors better than its control group,
acetylsalicylic acid. Interestingly, the writhing test of 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid with 0.6% acetic acid showed a
dose-dependent decrease and it significantly gave a lower nociceptive
response count compared with acetylsalicylic acid treated groups. It has
been considered that the writhing test could stimulate the signals
transmitted to central nervous system in response to pain generated by
irritation agents such as 0.6% acetic acid [20], the inhibition of pain by
common NSAIDs could inhibit the production of prostaglandins in
central nervous system by inhibiting its synthesized enzyme of COX-2
which contributes to the decreased sensitivity to nociceptors time [21].
Therefore, summarizing the results from Plantar Anestesiometer and in-
silico docking experiment, we postulated that our newly synthesized
drug, 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid, could act as a
better analgesic agent than acetylsalicylic acid through the peripheral
and central nervous systems by inhibiting the production of pros-
taglandins by common mechanism of action such as COX-2-inhibition.
4.5. Flow cytometry based platelet aggregation assay
To discover further advantage of 2-((3-(chloromethyl)benzoyl)oxy)
benzoic acid in cardiovascular disease, we postulated that in ac-
cordance with acetylsalicylic acid, 2-((3-(chloromethyl)benzoyl)oxy)
benzoic acid could also play a role as an anti platelet-aggregation drug
Fig. 5. Mouse platelet aggregation test with whole blood. Platelets in mouse plasma were labeled with CD31-APC or CD31-PE and mixed in 1:1 ratio before pre-
incubation and stimulation. Aggregation was measured by flow cytometry, 15min after pre-incubation with vehicle: suspending agent 3% PGA; ASA: with
0.58 mmol/kg bw of acetylsalicylic acid and 3 −CH2Cl: equimolar 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3 −CH2Cl). Each pre-incubation probe was
stimulated simultaneously with collagen. A. Dot Plot representative of double-colored event 15min after pre-incubation and stimulation with collagen. B.
Quantitative analysis of double-coloured events (box upper right only). Data are presented as the mean of % Total aggregation (double-coloured events in box upper
right divided with total events)± SEM (n=10). An asterisk indicates a significant difference compared with vehicle controls (P < 0.05).
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for cardioprotective effect by minimizing the thrombus formation.
Indeed the platelet aggregation phenomenon tested in flow cytometry-
based assay was significantly decreased in 0.58mmol/kg bw of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid treated mice (equivalent to
human dosage 500mg/60 kg bw), in comparison to the equimolar
acetylsalicylic acid treated animal group. It is already well known, that
the antithrombotic action of aspirin (acetylsalicylic acid) is due to the
inhibition of platelet function by acetylation of the platelet COX-1 [2].
However, the histopathological results as shown in Fig. 2 led us to
another hypothesis that the mechanism of action of 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid was presumably not directly or
partially associated with COX-1 inhibition due to the intact integrity of
gastric mucosal layer [22]. Therefore the antithrombotic action of 2-
((3-(chloromethyl)benzoyl)oxy)benzoic acid could be caused by an-
other common anti-aggregation mechanism associated with salicylic
acid derivative drugs. Tehrani et al. [23] demonstrated the influence of
acetylsalicylic acid on the disruption of blood plasma coagulation fac-
tors network such as fibrin formation. Other studies showed that an-
other salicylate derived anti-platelet agent namely triflusal has minor
gastrointestinal toxicity due to weaker COX-1 inhibition than acet-
ylsalicylic acid [24], which may be another possible reason for the dual
advantage of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid as an
Fig. 6. Tail bleeding time assay of 2-
((3-(chloromethyl)benzoyl)oxy)ben-
zoic acid and acetylsalicylic Acid by a
filter paper method. A. Representative
graphics are shown for blood spot of
incised mice tails (A) with suspending
agent 3% PGA acted as vehicle, (B)
with 0.58mmol/kg bw of acet-
ylsalicylic acid (ASA), or (C) equi-
molar O-(3-chloromethylbenzoyl)sal-
icylic acid (3 −CH2Cl), 30 min after
drug administration. Black arrow in-
dicates preliminary blood drop spot.
White arrow indicates the clockwise
blood drop position. Each spot re-
presents 30 s interval. Continuing
blood flow from the cut during the 30-
second interval was allowed to fall
separately. B. Quantitative analysis of
tail bleeding time by filter paper
method. Blood spot from 6a was
counted as described and represented
as bleeding time (in second) in this
diagram. Graphical result of vehicle:
suspending agent 3% PGA, ASA: with
0.58mmol/kg bw of acetylsalicylic
acid and 3 −CH2Cl: equimolar 2-((3-
(chloromethyl)benzoyl)oxy)benzoic
acid (3 −CH2Cl). Data are presented
as mean ± SEM (n=6). An asterisk
indicates a significant difference
compared with vehicle controls (P <
0.05). Two asterisks indicate a sig-
nificant difference compared with ve-
hicle controls (P < 0.05).
Scheme 1. Salicylic acid (IUPAC name: 2-hydroxybenzoic acid) reacted with 3-(chloromethyl)benzoyl chloride, with pyridine as the catalyst and the reactive group,
by using MicroSYNTH microwave (600W, 5min), yielded 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid and pyridin-1-ium chloride. The pyridin-1-ium chloride was
solved in water, nor was the products.
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analgesic-antiplatelet drug with significantly lower gastrointestinal
toxicity profile.
4.6. Tail bleeding time assay
To verify the anti-aggregation results, we conducted the classical
murine tail bleeding time assay with 0.58mmol/kg bw of 2-((3-
(chloromethyl)benzoyl)oxy)benzoic acid. The results generated from
this assay did not only indicate the platelet functionality, but also gave
us a broader spectrum to be considered regarding the coagulation fac-
tors and vascular integrity issue [25]. As expected with salicylic acid-
related drugs, the bleeding time was prolonged in 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid treated animal group. Additionally, the
bleeding pattern of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid
treated animals seemed to be more in amount compared with the
acetylsalicylic acid treated group. Therefore until further laboratory
and clinical investigation, we postulated that 2-((3-(chloromethyl)
benzoyl)oxy)benzoic acid is a better candidate of anti-platelet ag-
gregation drugs, which could contribute better than acetylsalicylic acid
in treating the patients with cardiovascular problems. Additionally, our
results as shown in Fig. 6 gave us some clue regarding the finding of
another mechanism apart from platelet COX-1 aggregation cascade
which could induce higher bleeding, simultaneously disrupt the platelet
function and has greater impact on blood homeostasis. The disruption
of plasma coagulation factors integrity was one of possible mechanism
caused by oral administration 2-((3-(chloromethyl)benzoyl)oxy)ben-
zoic acid to induce the antiplatelet aggregation.
5. Conclusion
The present study demonstrated that we could successfully synthe-
size a new compound related to salicylic acid namely 2-((3-(chlor-
omethyl)benzoyl)oxy)benzoic acid with a relative simple and easy
method, having higher purity grade, and higher reaction yield. Through
the observation of our animal models, we postulated that this new
compound had an excellent analgesic effect with no toxicity impact,
better than acetylsalicylic acid. Since this compound could induce anti-
platelet aggregation, it seemed that 2-((3-(chloromethyl)benzoyl)oxy)
benzoic acid could play another role as an anti-platelet aggregation
drug presumably by binding to its hypothetical target: COX-2 receptor
protein.
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